Sign In
Buy MESO
$14.17
-0.380 (-2.61%)
At Close: Jul 31, 2026
Calithera Terminating Partnership, And Other News: The Good, Bad And Ugly Of Biopharma
07:27am, Wednesday, 09'th Sep 2020
Calithera signals terminating partnership with Incyte. Lexicon reports dosing in Phase 2 clinical study for LX9211.
Mesoblast Before The PDUFA
07:53am, Monday, 31'st Aug 2020
Mesoblast's stem cell therapy candidate has had an outstanding advisory committee meeting where it was voted 9-1. Approval at PDUFA next month is a given.
Mesoblast Limited (MESO) CEO Silviu Itescu on Q4 2020 Results - Earnings Call Transcript
05:27am, Thursday, 27'th Aug 2020
Mesoblast Limited (NASDAQ:MESO) Q4 2020 Earnings Conference Call August 26, 2020 6:00 P.M. ET Company Participants Silviu Itescu - Chief Executive Officer and Managing Director Josh Muntner - Chief Fi
Mesoblast Limited 2020 Q4 - Results - Earnings Call Presentation
02:12am, Thursday, 27'th Aug 2020
The following slide deck was published by Mesoblast Limited in conjunction with their 2020 Q4 earnings call.
Mesoblast Limited Investors: Company Investigated by the Portnoy Law Firm
12:00pm, Wednesday, 19'th Aug 2020
Investors can contact the law firm at no cost to learn more about recovering their lossesLOS ANGELES, Aug. 19, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Mesoblast Limited ("Mesoblast" or t
NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Mesoblast Limited
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mesoblast Limited
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Mesoblast Limited (MESO) Investigation
08:00pm, Monday, 17'th Aug 2020
NEW YORK, NY / ACCESSWIRE / August 17, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mesoblast Limited (‘Mesoblast" or the "Company") (NASDAQ
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mesoblast Limited
MESO EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Mesoblast Limited – MESO
06:47pm, Sunday, 16'th Aug 2020
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Mesoblast Limited (NASDAQ: MESO) resulting from allegations th
Mesoblast Gets Favorable Votes From FDA Committee for Ryoncil
05:53pm, Friday, 14'th Aug 2020
Mesoblast (MESO) gets ODAC's vote in the ratio of 9:1 for GVHD drug.
5 Stock Gainers for Friday: Dillard's, Intrepid Potash, Suzano SA
05:41pm, Friday, 14'th Aug 2020
Intrepid Potash, Suzano SA, Mesoblast, Farfetched and Dillard's are among Friday's top gainers.
Why Mesoblast's Stock is Trading Higher Today
03:02pm, Friday, 14'th Aug 2020
Mesoblast (NASDAQ: MESO) shares are trading higher after the company announced the Oncologic Drugs Advisory Committee of the FDA voted in favor of its RYONCIL for efficacy in children with steroid-ref
TG Therapeutics Umbralisib Development, And Other News: The Good, Bad And Ugly Of Biopharma
12:57pm, Friday, 14'th Aug 2020
TG Therapeutics reports development for Umbralisib. Mesoblast gets FDA nod for Ryoncil.
NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the Oncologic Drugs Advisory C
